688180 君实生物-U
已收盘 08-28 15:00:01
资讯
新帖
简况
君实生物（688180）2026年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-28 06:18
君实生物（688180）2026年中报简析：营收净利润同比双双增长，盈利能力上升
君实生物（688180）披露2026年半年度报告，8月27日股价上涨0.25%
证券之星 · 08-27 19:27
君实生物（688180）披露2026年半年度报告，8月27日股价上涨0.25%
君实生物(688180.SH)发布半年度业绩，归母净利润2166.3万元，同比扭亏为盈
智通财经 · 08-27 00:17
君实生物(688180.SH)发布半年度业绩，归母净利润2166.3万元，同比扭亏为盈
君实生物：上半年净利润2166.3万元 同比扭亏为盈
格隆汇 · 08-26 18:07
君实生物：上半年净利润2166.3万元 同比扭亏为盈
君实生物（688180）披露股东减持股份结果公告，8月20日股价上涨8.44%
证券之星 · 08-20
君实生物（688180）披露股东减持股份结果公告，8月20日股价上涨8.44%
港股早盘反复扬升 恒指半日涨1.14% 中国生物制药（01177）涨16.18%
金吾财讯 · 08-20
港股早盘反复扬升 恒指半日涨1.14% 中国生物制药（01177）涨16.18%
每周股票复盘：君实生物（688180）机构连续五日大宗交易净买入超1.8亿
证券之星 · 08-16
每周股票复盘：君实生物（688180）机构连续五日大宗交易净买入超1.8亿
君实生物（688180）披露2026年中期业绩审议董事会会议安排，8月12日股价上涨0.36%
证券之星 · 08-12
君实生物（688180）披露2026年中期业绩审议董事会会议安排，8月12日股价上涨0.36%
君实生物（688180）披露股东减持股份结果公告，8月10日股价下跌0.84%
证券之星 · 08-10
君实生物（688180）披露股东减持股份结果公告，8月10日股价下跌0.84%
每周股票复盘：机构连续三日净买入君实生物（688180）
证券之星 · 08-09
每周股票复盘：机构连续三日净买入君实生物（688180）
君实生物（688180）披露截至2026年7月31日证券变动月报表，8月5日股价上涨2.51%
证券之星 · 08-05
君实生物（688180）披露截至2026年7月31日证券变动月报表，8月5日股价上涨2.51%
每周股票复盘：君实生物（688180）现两笔机构大宗净买入
证券之星 · 08-02
每周股票复盘：君实生物（688180）现两笔机构大宗净买入
君实生物（688180）披露关于回购公司H股股份一般性授权的议案获通过，7月27日股价上涨4.04%
证券之星 · 07-27
君实生物（688180）披露关于回购公司H股股份一般性授权的议案获通过，7月27日股价上涨4.04%
君实生物（688180）披露2026年度第二期科技创新债券发行结果，7月23日股价下跌0.48%
证券之星 · 07-23
君实生物（688180）披露2026年度第二期科技创新债券发行结果，7月23日股价下跌0.48%
君实生物宣布特瑞普利单抗联合化疗作为可切除II-III期非小细胞肺癌围手术期治疗的补充申请获受理
美股速递 · 07-22
君实生物宣布特瑞普利单抗联合化疗作为可切除II-III期非小细胞肺癌围手术期治疗的补充申请获受理
葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向
智通财经 · 07-21
葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向
每周股票复盘：君实生物（688180）拟回购不超10%H股股份
证券之星 · 07-12
每周股票复盘：君实生物（688180）拟回购不超10%H股股份
君实生物（688180）披露关于回购公司H股股份一般性授权的议案，7月8日股价下跌2.71%
证券之星 · 07-08
君实生物（688180）披露关于回购公司H股股份一般性授权的议案，7月8日股价下跌2.71%
每周股票复盘：君实生物（688180）授权复星万邦获2.15亿首付款
证券之星 · 07-05
每周股票复盘：君实生物（688180）授权复星万邦获2.15亿首付款
君实生物（688180）披露截至2026年6月30日证券变动月报表，7月3日股价上涨5.41%
证券之星 · 07-03
君实生物（688180）披露截至2026年6月30日证券变动月报表，7月3日股价上涨5.41%
加载更多
公司概况
公司名称：
上海君实生物医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2020-07-15
主营业务：
上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是拓益®、君迈康®、民得维®、君适达®。公司产品曾荣膺国家专利领域最高奖项“中国专利金奖”，并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。
发行价格：
55.50
{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":33.56,"timestamp":1787900401000,"preClose":35.57,"halted":0,"volume":24839094,"delay":0,"changeRate":-0.0565,"floatShares":766000000,"shares":1027000000,"eps":-0.4294,"marketStatus":"已收盘","change":-2.01,"latestTime":"08-28 15:00:01","open":35.53,"high":35.55,"low":33.54,"amount":853000000,"amplitude":0.0565,"askPrice":33.57,"askSize":132,"bidPrice":33.56,"bidSize":228,"shortable":0,"etf":0,"ttmEps":-0.4294,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":35.57,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":39.13,"lowLimit":32.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1026689871,"isCdr":false,"pbRate":5.8,"roa":"--","roe":"0.36%","epsLYR":-0.87,"committee":-0.120847,"marketValue":34456000000,"turnoverRate":0.0324,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-31。","afterMarket":{"amount":417452.84,"volume":12439,"close":33.56,"buyVolume":0,"sellVolume":5631,"time":1787902437746,"indexStatus":"已收盘 08-28 15:30:00","preClose":35.57},"hkstockBrief":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":18.46,"timestamp":1787904513002,"preClose":19.4,"halted":0,"volume":3549000,"delay":0,"premium":"-52.77"},"floatMarketCap":25720000000},"requestUrl":"/m/hq/s/688180","defaultTab":"news","newsList":[{"id":"2662036773","title":"君实生物（688180）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036773","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662036773?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:18","pubTimestamp":1787869085,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期君实生物发布2026年中报。截至本报告期末，公司营业总收入16.96亿元，同比上升45.18%，归母净利润2166.3万元，同比上升105.25%。本报告期君实生物盈利能力上升，毛利率同比增幅3.9%，净利率同比增幅93.96%。本文数据来源于君实生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800010947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662223701","title":"君实生物（688180）披露2026年半年度报告，8月27日股价上涨0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662223701","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662223701?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:27","pubTimestamp":1787830036,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，君实生物报收于35.57元，较前一交易日上涨0.25%，最新总市值为365.19亿元。君实生物于近日披露《2026年半年度报告》。本报告期营业收入为169,621.09万元，同比增长45.18%；利润总额为-3,338.02万元，上年同期为-48,521.16万元；归属于上市公司股东的净利润为2,166.30万元，上年同期为-41,269.56万元；归属于上市公司股东的扣除非经常性损益的净利润为-20,343.85万元，上年同期为-47,842.82万元。研发投入占营业收入的比例为37.96%，上年同期为60.39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700045876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0239","BK1161","01877","688180","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662453607","title":"君实生物(688180.SH)发布半年度业绩，归母净利润2166.3万元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662453607","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662453607?lang=zh_cn&edition=full","pubTime":"2026-08-27 00:17","pubTimestamp":1787761055,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物 披露2026年半年度报告，报告期公司实现营业收入16.96亿元，同比增长45.18%;归属于上市公司股东的净利润2166.3万元，同比扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润亏损2.03亿元，同比收窄;基本每股收益0.02元。报告期内，公司在创新药物的发现、研发、生产和商业化等方面皆有源头创新性、突破性进展，现金流情况良好，公司核心管理层及研发团队稳定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973587","title":"君实生物：上半年净利润2166.3万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973587","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662973587?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:07","pubTimestamp":1787738862,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688180","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660259400","title":"君实生物（688180）披露股东减持股份结果公告，8月20日股价上涨8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660259400","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660259400?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:31","pubTimestamp":1787218302,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，君实生物报收于40.45元，较前一交易日上涨8.44%，最新总市值为415.3亿元。公司于近日披露《关于股东减持股份结果公告》。公告显示，本次减持计划实施前，上海檀英持有君实生物59,459,326股，占总股本的5.7914%。因基金期限与流动性资金安排，上海檀英计划通过大宗交易方式减持不超过20,533,797股，减持期间为2026年5月20日至2026年8月19日。减持后持股数量为38,925,626股，持股比例降至3.7914%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK1583","BK0239","BK1515","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660944408","title":"港股早盘反复扬升 恒指半日涨1.14% 中国生物制药（01177）涨16.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660944408","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660944408?lang=zh_cn&edition=full","pubTime":"2026-08-20 12:11","pubTimestamp":1787199118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘反复扬升，截至午间收盘，恒指涨1.14%，国企指数涨1.42%，恒生科技指数涨1.54%。中国生物制药涨16.18%，石药集团涨13.47%，老铺黄金涨11.39%，周大福涨7.18%，药明生物涨6.47%。毛利率预计由2025年的55%下降至2026年的51%，经调整净利润率亦由14.5%大幅降至7%，相当于约95亿元人民币。海丰国际半日涨6.02%。详细来看，今年上半年归属于上市公司股东的净利润17.12亿元，同比增长2.44%；基本每股收益1.25元。期内实现营业收入130.71亿元，同比增长7.01%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988792","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","01877","IE0034224299.USD","BK1602","LU0244354667.USD","LU0791590937.USD","LU0634319403.HKD","02013","LU0039217434.USD","LU0593848301.USD","HSTECH","LU0307460666.USD","07500","SG9999002562.SGD","03032","LU2328871848.SGD","02833","BK1193","LU1023057109.AUD","HK0000288743.USD","BK1590","LU0310800965.SGD","LU0823426308.USD","LU1152091754.HKD","LU0359201885.HKD","SG9999001093.SGD","LU0128522157.USD","03347","LU1769817179.HKD","03033","LU0348825331.USD","LU2097828631.EUR","LU0128525689.USD","SBHMY","LU0043850808.USD","LU0516422440.USD","LU1993786604.SGD","09995","LU2351347302.SGD","SG9999006597.SGD","LU0672654166.SGD","BK1516","SG9999001051.SGD","LU2929501877.USD","LU1242518857.USD","LU0890818403.SGD","BK1151","83115","IE0003795394.USD","BK1578","LU0588546209.SGD","LU1251922891.USD","IE0032431581.USD","SG9999014674.SGD","BK1575","BK1589","BK1604","LU0051755006.USD","IE00BZ08YT58.USD","LU0348827113.USD","LU0417516571.SGD","LU1267930227.SGD","LU0326950275.SGD","LU1366334651.USD","03067","LU0516423091.SGD","LU2187417386.USD","IE00BYQNZ168.SGD","LU0359201612.USD","BK1526","BK1570","LU0181495838.USD","02696","LU1769817096.USD","LU2039709279.SGD","LU2242644610.SGD","09926","LU0516422366.SGD","LU0320764755.SGD","LU1226288253.USD","LU1303224171.USD","BK1103","01044","LU0072913022.USD","BK1116","SEA","BK1510","BK1171","LU0456846285.SGD","LU1226288170.HKD","LU0140636845.USD","LU1880383366.USD","CRHKY","LU0417516738.SGD","03898","LU1226287529.USD","LU0862451837.USD","LU0067412154.USD","LU0456827905.SGD","LU0979878070.USD","CJEWY","BOAT","09067","03037","LU2097828474.EUR","HK0000306685.HKD","IE0008368742.USD","688331","DRGN","HK0000320264.USD","80291","07226","LU0052750758.USD","LU0417516902.SGD","KSTmain","IE00BZ08YS42.EUR","LU1008478684.HKD","BK1109","LU0348767384.USD","LU2399975544.HKD","82800","LU1961090484.USD","LNVGY","SG9999001069.SGD","LU1328615791.USD","HK0000306701.USD","LU0359202008.SGD","BK1141","01093","HK0000320223.HKD","HHImain","HEGIY","LU0501845795.SGD","LU1951186391.HKD","IE00B5MMRT66.SGD","BK1104","LU0708995583.HKD","02800","LU2097828557.USD","03423","LU1226287792.SGD","IE0003895053.USD","00291","IE00BYTNYN87.SGD","LU1807302812.USD","LU0463099449.HKD","LU1720050803.USD","LU1960683339.HKD","BK1591","SG9999006514.SGD","LU0052756011.USD","BK1615","IE0031814852.USD","LU1366334578.USD","LU0862451753.SGD","BK1095","09626","03088","LU1235295612.USD","03417","07552","BK1521","LU0029874061.USD","BK1227","81024","07200","LU1969619763.USD","SG9999003461.SGD","LU0315179316.USD","01024","SG9999004220.SGD","LU0320764599.SGD","SG9999011746.SGD","LU0561508036.HKD","LU1770034418.SGD","06181","IE00B0169L03.USD","IE00B0JY6N72.USD","01548","LU1188198961.HKD","LU0880133367.SGD","BK1224","BK1587","LU0348783233.USD","LU2476274720.SGD","HK0000165453.HKD","07300","BK1502","ZTO","BK1515","LU2097828805.USD","BK1207","KURE","LU0572939691.SGD","02269","LU2488822045.USD","03115","IE0008369823.USD","WXXWY","01308","BK1588","IE00B031HY20.USD","688180","LU0370786039.SGD","LU1046422090.SGD","LU0543330483.HKD","BK1544","09088","MCHmain","HSI","LU0328353924.USD","LU0540923850.HKD","BK1601","LU0348766576.USD","SG9999002463.SGD","BK1583","LU0210526637.USD","IE00B12V2V27.USD","00992","LU0048580855.USD","SGXZ90724238.SGD","513600","LU0128526141.USD","80992","688187","BK1576","LU0823426480.USD","LU0819121731.USD","LU0049112450.USD","300347","BK1618","IE00BPRC5H50.USD","LU1152091168.USD","LU2778985437.USD","IE00B29SXG58.USD","LU0856984785.SGD","BILI","BK1565","TCHI","BK1607","LU0572944931.SGD","LU1813983027.USD","IE0003851619.USD","LU0327786744.USD","BK1541","LU0516422952.EUR","LU1794554557.SGD","02057","LU2097828714.EUR","01929","BK1161","BK1574","LU2476274308.USD","IE00BZ08YR35.GBP","03419","LU1688375341.USD","LU0029875118.USD","LU1719994722.HKD","BK1608","LU1226287875.USD","BK1545","LU2279858448.HKD","LU0348784397.USD","LU0348735423.USD","SOCL","HK0000288784.HKD","LU0264606111.USD","LU1242518931.SGD","02837","LU0211977185.USD","LU0572940350.SGD","LU1171460220.USD","LU3063872942.SGD","BK1518","09115","BK1500","IE00B543WZ88.USD","LU0314109678.HKD","LU1328277881.USD","LU0791591158.USD","BK1610","LU0516423174.USD","BK1191","BK1180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175030","title":"每周股票复盘：君实生物（688180）机构连续五日大宗交易净买入超1.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175030","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175030?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:24","pubTimestamp":1786818253,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，君实生物报收于39.89元，较上周的39.24元上涨1.66%。本周关注点来自交易信息汇总：8月10日至14日，君实生物连续五日出现大宗交易，机构合计净买入1.8173亿元。来自股本股东变化：股东上海檀英及贺铭在2026年6月16日至8月10日合计减持1092.26万股，占总股本1.0639%。君实生物H股公告上海君实生物医药科技股份有限公司董事会将于2026年8月26日召开会议，审议本集团截至2026年6月30日止六个月的中期业绩，并处理其他事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","01877","BK1161","BK1515","BK0239","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658031029","title":"君实生物（688180）披露2026年中期业绩审议董事会会议安排，8月12日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658031029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658031029?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543824,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，君实生物报收于38.63元，较前一交易日上涨0.36%，最新总市值为396.61亿元。该股当日开盘38.1元，最高40.56元，最低38.03元，成交额达10.33亿元，换手率为3.42%。近日，君实生物发布公告称，公司董事会谨定于2026年8月26日举行董事会会议，以考虑及通过本集团截至2026年6月30日止六个月的中期业绩，并处理其他事项。本次会议由董事会主席熊俊先生召集。公告同时列出了截至公告日期的董事会成员名单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877","BK0239","BK1583","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658882932","title":"君实生物（688180）披露股东减持股份结果公告，8月10日股价下跌0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658882932","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658882932?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:04","pubTimestamp":1786370699,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，君实生物报收于38.91元，较前一交易日下跌0.84%，最新总市值为399.49亿元。近日，君实生物发布《关于股东减持股份结果公告》。公告显示，本次减持计划实施前，贺铭女士持有公司股份3,531,380股，占公司总股本的0.3440%。因个人资金需求，贺铭女士计划通过集中竞价方式减持不超过882,600股，减持比例不超过公司总股本的0.0860%。本次减持已实施完毕，当前持股数量为2,647,980股，持股比例降至0.2579%。本次减持符合相关法规及此前披露的减持计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000033616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK0239","BK1583","688180","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658567360","title":"每周股票复盘：机构连续三日净买入君实生物（688180）","url":"https://stock-news.laohu8.com/highlight/detail?id=2658567360","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658567360?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:20","pubTimestamp":1786209620,"startTime":"0","endTime":"0","summary":"来自公司公告汇总：截至2026年7月31日，君实生物H股与A股股本及已发行股份无变动。交易信息汇总8月7日君实生物现1笔大宗交易，机构净买入2924.25万元8月6日君实生物现1笔大宗交易，机构净买入2754万元8月5日君实生物现1笔大宗交易，机构净买入2802万元公司公告汇总上海君实生物医药科技股份有限公司截至2026年7月31日的证券变动月报表显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1583","01877","BK1515","688180","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657252319","title":"君实生物（688180）披露截至2026年7月31日证券变动月报表，8月5日股价上涨2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657252319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657252319?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:36","pubTimestamp":1785940577,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，君实生物报收于37.6元，较前一交易日上涨2.51%，最新总市值为386.04亿元。该股当日开盘36.54元，最高38.2元，最低36.45元，成交额达5.6亿元，换手率为1.94%。公告显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于港交所上市，A股于上交所科创板上市。确认公众持股量符合上市规则要求，且所有证券发行均已获董事会授权并遵守相关法规。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1161","161027","BK1583","BK0239","688180","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316636","title":"每周股票复盘：君实生物（688180）现两笔机构大宗净买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316636","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316636?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:40","pubTimestamp":1785606024,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，君实生物报收于36.51元，较上周的35.88元上涨1.76%。君实生物当前最新总市值374.84亿元，在生物制品板块市值排名3/51，在两市A股市值排名508/5202。7月27日君实生物发生1笔大宗交易，机构净买入2039.95万元。会议审议通过《关于回购公司H股股份一般性授权的议案》，该议案为特别决议议案，获出席股东所持表决权三分之二以上通过，并对A股中小投资者单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1515","01877","BK1161","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045230","title":"君实生物（688180）披露关于回购公司H股股份一般性授权的议案获通过，7月27日股价上涨4.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654045230?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:13","pubTimestamp":1785161631,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，君实生物报收于37.33元，较前一交易日上涨4.04%，最新总市值为383.26亿元。该股当日开盘36.09元，最高38.2元，最低35.41元，成交额达6.5亿元，换手率为2.29%。出席会议股东共353人，代表有表决权股份总数270,778,987股，占公司总表决权数的26.3950%。会议审议通过《关于回购公司H股股份一般性授权的议案》，该议案为特别决议议案，获出席股东所持表决权三分之二以上通过，并对A股中小投资者单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK1515","688180","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745665","title":"君实生物（688180）披露2026年度第二期科技创新债券发行结果，7月23日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653745665?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:50","pubTimestamp":1784800244,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，君实生物报收于37.21元，较前一交易日下跌0.48%，最新总市值为382.03亿元。君实生物于近日披露《关于2026年度第二期科技创新债券发行结果的公告》。公告显示，上海君实生物医药科技股份有限公司2026年度第二期科技创新债券已发行完毕，实际发行总额3亿元，发行利率2.59%，期限3年，起息日为2026年7月22日，兑付日为2029年7月22日。募集资金已于2026年7月22日到账。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1515","BK1583","688180","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197103812","title":"君实生物宣布特瑞普利单抗联合化疗作为可切除II-III期非小细胞肺癌围手术期治疗的补充申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1197103812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197103812?lang=zh_cn&edition=full","pubTime":"2026-07-22 07:12","pubTimestamp":1784675521,"startTime":"0","endTime":"0","summary":"君实生物宣布，其核心产品特瑞普利单抗联合化疗，作为可切除II-III期非小细胞肺癌围手术期治疗的补充新药上市申请，已获得国家药品监督管理局药品审评中心受理。该研究旨在评估特瑞普利单抗联合化疗对比单纯化疗，用于可切除II-III期非小细胞肺癌患者围手术期治疗的有效性和安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733442","title":"葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653733442?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:16","pubTimestamp":1784625396,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。此外，君实生物新进持仓前十，信立泰跌出十大重仓。葛兰在季报中指出，2026年第二季度，市场风格分化显著，医药生物板块经历大幅震荡，整体走势弱于大盘。葛兰表示，第三季度创新药及产业链仍是布局的主要方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK1574","BK4581","XLV","XBI","BK4550","BK1161","IXJ","01877","BK1515","MEDX","LNGR","06978","159992","159760","BK4588","BK4585","VHT","BK0239","688180","BK1583","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154819","title":"每周股票复盘：君实生物（688180）拟回购不超10%H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650154819?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:58","pubTimestamp":1783792690,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，君实生物报收于37.6元，较上周的37.99元下跌1.03%。本周关注点公司公告汇总：君实生物拟回购不超过已发行H股总数10%的股份。君实生物2026年第一次临时股东会会议资料上海君实生物医药科技股份有限公司提请2026年第一次临时股东会审议《关于回购公司H股股份一般性授权的议案》。授权期限至2026年年度股东会结束或股东会决议撤回授权之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK0239","BK1583","688180","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649991088","title":"君实生物（688180）披露关于回购公司H股股份一般性授权的议案，7月8日股价下跌2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649991088","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649991088?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:16","pubTimestamp":1783520182,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，君实生物报收于35.9元，较前一交易日下跌2.71%，最新总市值为368.58亿元。该股当日开盘36.5元，最高37.25元，最低35.8元，成交额达6.99亿元，换手率为2.51%。近日，君实生物发布《关于回购公司H股股份一般性授权的议案》相关公告。授权事项包括制定具体回购方案、开立境外账户、办理外汇登记、履行监管备案程序、注销股份或作为库存股持有等。授权期限至2026年年度股东会结束或股东会决议撤回授权之日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK1515","688180","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649946426","title":"每周股票复盘：君实生物（688180）授权复星万邦获2.15亿首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2649946426","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649946426?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:12","pubTimestamp":1783188734,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，君实生物报收于37.99元，较上周的29.68元上涨28.0%。本周关注点来自公司公告汇总：君实生物授权复星万邦开发抗IL-17A单抗，获2.15亿元首付款。公司可获得2.15亿元首付款，最高11.25亿元里程碑付款，以及大中华地区净销售额双位数百分比的分级销售提成。股本总额维持为人民币1,026,689,871元。H股和A股股票期权激励计划已于2025年9月29日获批准采纳，当月无新增行权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","01877","BK1161","BK1515","BK0239","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648127661","title":"君实生物（688180）披露截至2026年6月30日证券变动月报表，7月3日股价上涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648127661","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648127661?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:20","pubTimestamp":1783088432,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，君实生物报收于37.99元，较前一交易日上涨5.41%，最新总市值为390.04亿元。近日，君实生物发布截至2026年6月30日的证券变动月报表。公告显示，公司H股和A股的法定注册资本、已发行股份及库存股均无变动。H股总数为260,295,700股，于港交所上市；A股总数为766,394,171股，于上交所科创板上市。库存股为815,871股A股。股份期权计划方面，H股和A股股票期权激励计划分别于2025年9月29日获批准采纳，当月无新增行权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK1515","688180","BK0239","161027","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787941181940,"stockEarnings":[{"period":"1week","weight":-0.1032},{"period":"1month","weight":-0.0688},{"period":"3month","weight":-0.0199},{"period":"6month","weight":-0.0129},{"period":"1year","weight":-0.2368},{"period":"ytd","weight":-0.0176}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37707人(较上一季度减少1.22%)","perCapita":"20324股","listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层","registeredCapital":"102668万元","survey":" 上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是拓益®、君迈康®、民得维®、君适达®。公司产品曾荣膺国家专利领域最高奖项“中国专利金奖”，并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。","listedPrice":55.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物-U(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物-U(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物-U,688180,君实生物-U股票,君实生物-U股票老虎,君实生物-U股票老虎国际,君实生物-U行情,君实生物-U股票行情,君实生物-U股价,君实生物-U股市,君实生物-U股票价格,君实生物-U股票交易,君实生物-U股票购买,君实生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物-U(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物-U(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}